Core Viewpoint - PolTREG S.A. has initiated a Phase II clinical trial for PTG-007, targeting pre-symptomatic type 1 diabetes, aiming to develop the first therapy to prevent the onset of the disease symptoms [1][3][7] Group 1: Clinical Trial Details - The Phase II trial, named "Pre-Treg," will enroll up to 150 genetically high-risk children and adolescents aged 3–18 who have not yet shown clinical symptoms of type 1 diabetes [1][4] - The study will be randomized and placebo-controlled, with recruitment ongoing at three academic centers in Poland and six additional clinical hospitals set to begin enrollment soon [4][6] - A parallel study has been proposed to the FDA, which could potentially be registrational, allowing Polish patients to be included in the U.S. statistical analysis [2][6] Group 2: Financial Support and Market Potential - PolTREG has received a non-dilutive grant of PLN 31.7 million (approximately $11.3 million) from the Polish Medical Research Agency to support the Phase II trial [4][6] - The CEO of PolTREG, Prof. Piotr Trzonkowski, emphasized the significant market and partnership potential of PTG-007 if the trial confirms its efficacy [3][7] Group 3: Therapy Mechanism and Pipeline - PTG-007 is an autologous cell therapy designed to be administered at the earliest stage of type 1 diabetes development, with the goal of halting disease progression before symptoms appear [5][8] - PolTREG is also developing multi-edited, allogeneic CAR-T regulatory cell therapies to treat patients diagnosed with symptomatic type 1 diabetes, creating a comprehensive pipeline for all stages of the disease [6][8] Group 4: Company Expansion and Collaboration - PolTREG has established its U.S. subsidiary, Immuthera, to develop cell-based therapies under the U.S. FDA regulatory framework [9][11] - The company has partnered with Noble Capital Markets, Inc. and Kinexum Services LLC to support its U.S. regulatory strategy and is collaborating with Antion Biosciences for next-generation therapies [9][11]